Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma

NCT03147885 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT03147885
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03147885 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Investigator Initiated Study of RCHOP in Combination With Selinexor (KPT-330) in B Cell Non-Hodgkin's Lymphoma
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 20, 2017
Completion date
December 31, 2027
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, recurrent b-cell non-hodgkin lymphoma, recurrent extranodal marginal zone lymphoma, recurrent follicular lymphoma, recurrent indolent adult non-hodgkin lymphoma, recurrent mantle cell lymphoma, recurrent marginal zone lymphoma, recurrent waldenstrom macroglobulinemia, refractory b-cell non-hodgkin lymphoma, refractory extranodal marginal zone lymphoma, refractory follicular lymphoma, refractory mantle cell lymphoma, stage iii non-hodgkin lymphoma, stage iv non-hodgkin lymphoma, transformed recurrent non-hodgkin lymphoma